- Did you mean
- bnt162b2 vaccines
Search results - 15 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
study teams (in addition to the named authors) Source: Euro Surveill, Volume 28, Issue 47 (2023) Keywords: Adult BNT162 Vaccine COVID-19 Europe Hospitalization Humans RNA, Viral SARS-CoV-2 Vaccine ...
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
J Transplant, Volume 23, Issue 5 (2023) Keywords: Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine Breakthrough Infections Cohort Studies COVID-19 Humans Immunoglobulin G Interferon-gamma Kidney ...
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.
Antibodies, Viral BNT162 Vaccine Breakthrough Infections COVID-19 COVID-19 Vaccines Humans Immunity nursing homes Population Groups RNA, Messenger SARS-CoV-2 Abstract: BACKGROUND: Nursing home residents, ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162 b2 (Pfizer-BioNTech) suggest that a fractional dose induces ...
Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign.
none, one or two BNT162 b2 vaccine doses. RESULTS: We found that during the primary vaccination campaign with 59% of the study population fully vaccinated, 74% had SARS-CoV-2 antibodies. Among fully ...
Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.
study compares a third dose of BNT162 b2 after double-dose BNT162 b2 (homologous) versus ChAdOx1 (heterologous) vaccination in cancer patients. EXPERIMENTAL DESIGN: 442 subjects (315 patients and 127 ...
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
Stéphanie Humblet-Baron Source: Front Immunol, Volume 13 (2022) Keywords: 2019-nCoV Vaccine mRNA-1273 Antibodies, Viral BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans Immunocompromised Host mRNA Vaccines ...
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.
Volume 13 (2022) Keywords: BNT162 Vaccine COVID-19 Cytokines Female Humans Intercellular Signaling Peptides and Proteins Neoplasms Placenta Growth Factor vaccines Abstract: BACKGROUND: Patients with ...
Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
over Bayes Theorem Belgium BNT162 Vaccine Contact Tracing COVID-19 Humans middle aged RNA, Viral SARS-CoV-2 Vaccination Vaccine Efficacy vaccines Abstract: BACKGROUND: During the first half of 2021, we ...
Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.
Wyndham-Thomas; Lucy Catteau Source: Viruses, Volume 14, Issue 4 (2022) Keywords: Ad26COVS1 Adult Belgium BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans incidence Prospective Studies Risk Factors SARS-CoV-2 ...